Promoter holding
64.27%
AP
Aurobindo Pharma Ltd - Due diligence report
A 360° intelligence report on Tergene Biotech: trust score, financial health, credit view, compliance, directors, growth and distress signal…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹349
50% off
New user
Or enjoy up to 50% off with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Tergene Biotech — 360° Intelligence Report
Generated from MCA filings & public records77/100
Trust Score
Low Risk
Tergene Biotech is assessed as Low Risk with a Trust Score of 77/100. Tergene Biotech is an active public limited indian non-government company incorporated in 1986, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a high compliance risk and low financial risk profile.
Report generated on 28 Jun 2026 from the latest processed filings. Aurobindo Pharma Ltd snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
77/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreCaution Indicated
42/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
95/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
95/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
80/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
75/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Consolidated · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 95/100 Low Risk
- Liabilities ≈ 38% EBITDA - serviceable.
- Moderate gearing (D/E 1.42).
- Working-capital cover adequate.
- Profitable - internal accruals available.
- Externally credit-rated (AA+).
Charges position: 1 open (2,000.00 cr) · 43 satisfied (4,387.54 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| State Bank Of India | 4 | 48.0 cr |
| State Bank Of Hyderabad | 1 | 48.0 cr |
| Ifci Limited | 4 | 48.0 cr |
| Others | 2 | 48.0 cr |
| Icici Bank Limited | 2 | 48.0 cr |
| Andhra Bank | 3 | 48.0 cr |
Compliance Score: 42/100 Caution Indicated
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Flagged by authority: BSE, SEBI.
- Litigation present in 4 court forum(s).
- Delayed payments to MSME suppliers disclosed (421 disclosure(s)).
- 23 active GST registration(s).
Legal cases on record (4)
05
Director Intelligence
Stability score: 80/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| ADI REDDY BADDIGAM | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SANTANU MUKHERJEE | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| DEEPALI PANT RAJEEV JOSHI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| NITYANANDA REDDY KAMBAM | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| MADAN MOHAN REDDY METTU | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| VENKATA RAMPRASAD REDDY PENAKA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SATAKARNI MAKKAPATI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| GIRISH PAMAN VANVARI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SANTHANAM SUBRAMANIAN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Mr. B. Adi Reddy | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SARATH CHANDRA REDDY PENAKA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| MANGALAM RAMASUBRAMANIAN KUMAR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Mr. S.Subramanian | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Santhanam Subramanian | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Adi Reddy Baddigam | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 15 directors on the board.
- No disqualified or deactivated DINs.
- 4 director exits in 3 years - high churn.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2024)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2024 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
6
Group entities
10
Capital events
28 allotment(s) · 0 transfer(s)
Promoters hold a majority stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| 1980 Puren Pharma Gmbh | Subsidiary Company | 74.00% |
| Acrotech Biopharma Inc. (formerly Acrotech Biopharma Llc) | Subsidiary Company | 74.00% |
| Agile Pharma B.v. | Subsidiary Company | 74.00% |
| All Pharma (shanghai) Trading Co Ltd | Subsidiary Company | 74.00% |
| Apl Healthcare Limited | Subsidiary Company | 74.00% |
| Apitoria Pharma Private Limited | Subsidiary Company | 74.00% |
| Apl Swift Services (malta) Ltd | Subsidiary Company | 74.00% |
| Sameko Farma B.v. | Subsidiary Company | 74.00% |
| Vespyr Brands Llc (formerly Known As Vespyr Brands, Inc) | Subsidiary Company | 74.00% |
| Apotex Europe B.v. | Subsidiary Company | 74.00% |
Key managerial personnel: NITYANANDA REDDY KAMBAM (Managing Director) · MADAN MOHAN REDDY METTU (Whole-time director) · SANTHANAM SUBRAMANIAN (CFO) · Mr. S.Subramanian (CFO)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 75 · Distress 90
Growth signals & trust indicators
Steady revenue growth: +2.1x over 4 year(s).
Profit expanded 24% year-on-year.
Net margin improved to 0.86.
Operating for 39+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Compliance score is weak (42/100).
1 open charge(s) registered - assets are encumbered.
MSME payment delays disclosed - latest outstanding 2.02 cr.
4 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence67/100
Review suggested
Suitability as a supplier / customer counterparty.
- Check the compliance flags before onboarding.
- No distress signals on file.
- Financial filings available for verification.
Banker assessment82/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 1 open charge(s) of 2,000.00 cr already registered.
- Compliance gaps should be priced into terms.
Investor view82/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 3 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events10 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
06 May 2024
Director ceased
MANGALAM RAMASUBRAMANIAN KUMAR
01 Apr 2024
Director appointed
MANGALAM RAMASUBRAMANIAN KUMAR (Director)
25 Mar 2024
Director ceased
DEEPALI PANT RAJEEV JOSHI
10 Feb 2024
Director appointed
DEEPALI PANT RAJEEV JOSHI (Director)
25 Dec 2023
Director ceased
SATAKARNI MAKKAPATI
09 Nov 2023
Director appointed
SATAKARNI MAKKAPATI (Director)
25 Aug 2023
Director ceased
SIVAKUMARAN MEENAKSHISUNDERAM
31 Mar 2023
Director ceased
SANTANU MUKHERJEE
09 Feb 2023
Director appointed
SANTANU MUKHERJEE (Director)
12 Nov 2022
Director ceased
SARATH CHANDRA REDDY PENAKA
01 Jan 2022
Director ceased
GOVINDARAJAN NARAYANAN
Director ceased
NITYANANDA REDDY KAMBAM
26 Aug 2021
Director ceased
GIRISH PAMAN VANVARI
10
Key Observations
Auto-generated from the data aboveRevenue grew 61% over the last 4 financial year(s).
Net profit margin moved from 38% to 1.42.
Debt-to-equity stands at 2.1x - manageable leverage.
Net worth is positive.
15 active director(s) / partner(s); board looks stable and experienced.
23 active GST registration(s) indicate ongoing business operations.
Operates a group structure with 6 subsidiary(ies) - assess on a consolidated basis.
Carries an external credit rating of AA+ from Indiarating.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a majority stake as per the FY 2024 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 28 security allotment(s) - amounts available in the full report.
66 overseas direct investment(s) (ODI) on record - international footprint.
| Company | CIN | Location |
|---|---|---|
| Aarti Industries | L24110GJ1984PLC007301 | Vapi, Gujarat, India |
| Msn Laboratories | U24239TG2003PTC041583 | Hyderabad, Telangana, India |
| Alkem Laboratories | L00305MH1973PLC174201 | Mumbai, Maharashtra, India |
| Seruminstitute | U80903PN1984PTC032945 | Pune, Maharashtra, India |
| Haldiapetrochemicals | U24100WB2015PLC205383 | Kolkata, West Bengal, India |
| Sun Pharma Laboratories Limited | U25200GJ1997PLC133846 | Vadodara, Gujarat, India |
| Lupin | L24100MH1983PLC029442 | Mumbai, Maharashtra, India |
| Grasim | L17124MP1947PLC000410 | Ujjain, Madhya Pradesh, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Tergene Biotech before audits and certifications: compliance score 42/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Tergene Biotech: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Favourable lending indicators. Credit risk score 95/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 75/100, margin trends, ownership structure and peer set for Tergene Biotech - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Review suggested. Trust score 77/100, distress signals and MSME payment-delay disclosures - know whether Tergene Biotech pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (4 case(s) on record), regulatory flags, charge documents trail and director networks for Tergene Biotech - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Tergene Biotech an active company?
Tergene Biotech has MCA status “Active” with a compliance score of 42/100 (Caution Indicated).
Is Tergene Biotech financially healthy?
Tergene Biotech has a Financial Health Score of 95/100 (Low Risk) based on its filed financial statements.
Should I do business with Tergene Biotech?
Its overall Trust Score is 77/100 (Low Risk). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Tergene Biotech?
Promoters hold a majority stake - exact percentages are in the full report. 15 active director(s) are on record.
Does Tergene Biotech have loans or charges against its assets?
1 open charge(s) are registered against its assets, and 43 earlier charge(s) stand satisfied.
Is Tergene Biotech up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 42/100 (Caution Indicated).
Is it risky to lend to Tergene Biotech?
Its Credit Risk Score is 95/100 (Low Risk). Banker verdict: Favourable lending indicators.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
